Inappropriate inhaled corticosteroid prescribing in chronic obstructive pulmonary disease patients | Zendy

Harrison Amelia | Zendy; Borg Brigitte | Zendy; Thompson Bruce | Zendy; Hew Mark | Zendy; Dabscheck Eli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Inappropriate inhaled corticosteroid prescribing in chronic obstructive pulmonary disease patients

Author(s) -

Harrison Amelia,

Borg Brigitte,

Thompson Bruce,

Hew Mark,

Dabscheck Eli

Publication year - 2017

Publication title -

internal medicine journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.596

H-Index - 70

eISSN - 1445-5994

pISSN - 1444-0903

DOI - 10.1111/imj.13611

Subject(s) - medicine , bronchodilator , copd , guideline , inhaler , medical prescription , pulmonary disease , bronchodilator agents , inhaled corticosteroids , pulmonary function testing , obstructive lung disease , lung function , corticosteroid , intensive care medicine , asthma , physical therapy , anesthesia , lung , pathology , pharmacology

The Australian National Chronic Obstructive Pulmonary Disease ( COPD ) guidelines recommend that inhaled corticosteroids ( ICS ) be reserved for patients with a post‐bronchodilator forced expiratory volume in 1 s ( FEV 1 ) less than 50% predicted and those who experience ≥2 exacerbations in 12 months. In total, 707 COPD patients were identified from the lung function test database at our tertiary hospital; 52.4% of patients with a post‐bronchodilator FEV 1 ≥50% were prescribed an ICS . Significant discordance exists between guideline recommendations and inhaler prescription.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research